DexCom is trading 10.6% up today at $82.47 after reporting better-than-expected second quarter 2026 results and raising its full-year guidance.
- The company delivered 13% revenue growth and a significant 590-basis-point jump in operating margin.
- Management outlined a strategic pivot toward the large non-insulin Type 2 diabetes market, which investors are rewarding despite broader weakness in the healthcare sector.